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Back ground: Among the various chronic serious complications of Diabetes 
mellitus foot related complications top the list. The life time risk of developing 
foot ulcer is 25 % and the annual incidence is 2-3% and leads to devastating 
consequence limb amputation. Diabetic foot ulcers fail to heal and become chronic 
due to repetitive trauma, infection and ischemia that are characterized by 
inappropriate inflammation, disproportionate collagen synthesis, degradation and 
deficient growth factors such as VEGF. Conventional treatments fail to treat 
underlying pathogenesis. Pulsed Electromagnetic Field therapy is a new modality 
which is found to interact at various steps in wound healing and up-regulates 
growth factors such as VEGF.    
 
Aim & Objective: 
To evaluate the effect of Pulsed Electro Magnetic Field therapy on chronic 
diabetic foot ulcers 
 
Materials & Methods: 
Thirty type 1 and 2 diabetic patients with chronic non healing diabetic foot 
ulcer of duration 4- 6weeks with Wagner’s foot ulcer grade 1 and 2 were exposed 
to PEMF therapy for 45 min /day for 30 days. The wound size and dimensions, 
granulation tissue, exudates, serum VEGF levels were noted before and after the 
PEMF therapy.  
 
Result: 
The results were analyzed using paired t’ test. The wound dimensions such 
as length, width, surface area, depth decreased significantly. Healthy granulation 
tissue and reduction in exudates were also observed. Significant elevation in 
Serum VEGF levels was also observed. All these results substantiate that PEMF 
therapy has enhanced wound healing. 
 
 
Conclusion: 
Decreased wound dimensions, formation of healthy granulation tissue, 
reduction in exudate and elevated serum VEGF levels indicate that PEMF enhance 
wound healing. No side effects were reported .Thus PEMF can be an effective and 
safe adjunct therapy for treating chronic non healing diabetic foot ulcers.   
 
Keywords: Diabetic patients, PEMF, Wagner’s grade, wound dimensions, 
granulation tissue, exudates, VEGF. 
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Introduction 
Diabetes Mellitus is a common metabolic endocrine disorder, once 
prevalent in developed countries has become the leading “Global epidemic” 
(Apleqvist et al1). “World Health Organization estimated that in the year 2000, 
roughly 3% of the total world population had Diabetes” (Armstrong DG et al2).  
Globally 177 million people had affected by Diabetes in 2000 this may rise 
to 366 million by 2030 (International Diabetes Federation; 20033, International 
diabetes federation Diabetes atlas 20114, International Diabetes Federation 20125, 
Wild S, Roglic G et al6). 
This is due to changes in life style, dietary patterns. In India around 
61million of general population affected in 2011 which may rise to 101 million by 
2030 (International diabetes federation Diabetes atlas 2011 4, International 
Diabetes Federation 2012 5, Wild S, Roglic G et al6, Alvin C et al7). 
Diabetes mellitus remains a leading cause of morbidity and mortality in 
both developed and developing countries and imposes a heavy burden on the 
health services (Wild S, Roglic G et al6, Alvin C et al7).   
Global rise in incidence has resulted in parallel increase in the incidence of 
Diabetic related complications.  
Among the various chronic serious complications of Diabetes, foot related 
complications top the list (Wild S, Roglic G6, Vileikyte Let al8, Reiber GE et al9). 
[2] 
 
The life time risk of developing foot ulcer in individuals with diabetes mellitus is 
25 % and the annual incidence is 2-3% ( Vileikyte L et al 8, Reiber GE et al9). 
Development of foot ulcer changes the quality of life in patients leading to 
devastating consequences like limb amputation and remains the major risk factor 
for all non traumatic foot amputations (Wild S, Roglic Get al6, Vileikyte L et al8, 
Reiber GE et al 9, Leung PC et al10).   
More than a million lower leg amputations are performed each year 
worldwide due to diabetes and every 30 second at least one lower limb is 
amputated (International Diabetes Federation 200511, Boulton, A. J et al 12). 
In India around 100,000 leg amputations are carried out per year 
(Contemporary management of the Diabetic foot13). 
The 2005 international diabetic federation reports that 85% of diabetes-
related lower extremity amputations are preceded by a foot ulcer (Larsson, J et 
al14). “Foot problems account for up to 15% of healthcare resources in developed 
countries and 40% in developing countries” (International diabetes federation 
Diabetes atlas 2011 4, International Diabetes Federation 2012 5) 
These amputations are potentially preventable. It has been established that a 
case strategy that combines prevention, multidisciplinary treatment of foot ulcers, 
appropriate organization can lead to significant reductions in amputation rates up 
to 85% (Larsson, J et al14). 
[3] 
 
Risk factors: 
Multiple contributory factors play a role in the pathogenesis of diabetic foot 
ulcers (Larsson, J et al14). 
A triad of neuropathy, vascular and biomechanical changes in the foot are 
considered to be the predisposing factors for the development of ulcers. Peripheral 
neuropathy and vascular changes are the two major factors that head the list 
(Contemporary management of the Diabetic foot13, Larsson, J et al14). 
Neuropathy, vascular changes or a combination of both produce mechanical 
stress in the foot and precipitate ulcers (Larsson, J et al 14, Armstrong DG et al15,   
Bowering CK et al16). Most of foot ulcers are of neuropathic in origin. Around 55 
to 60% of diabetic foot ulcers are caused by neuropathy (Dyck PJ et al 17). 
Old age, duration of diabetes, male gender, alcohol intake, poor glycemic 
control and smoking are other contributory factors in the pathogenesis of foot 
ulcers (Bowering CK et al.16, Dyck PJ et al17). 
Pathogenesis: 
Hyperglycemia induced metabolic abnormalities leads to peripheral 
neuropathy (Zochodone DW et al 18 Huijberts MS et al19) .Hyperglycemic status 
elevates the enzymes aldose reductase and sorbitol dehydrogenase of polyol 
pathway, which converts much of intracellular glucose to sorbitol, and fructose 
(Huijberts MS et al 19 Feldman ELet al 20).  
[4] 
 
These sugars accumulate, decrease myoinositol synthesis in the neuron ,this 
is pre requisite for normal nerve conduction.  
Reactive oxidative species (ROS) also accumulate and reduces nitric oxide 
synthesis which is a vasodilator. As a result the nerve cell undergoes severe 
oxidative stress, and an increased vasoconstriction resulting in ischemia finally 
leading to nerve injury and nerve death ensues (Feldman EL et al20).   
Abnormal non enzymatic glycosylation of cell proteins takes place which 
cross link with collagen and extracellular matrix proteins and decrease synthesis of  
nitric oxide,  produce abnormal  endothelial function with alteration in 
extracellular matrix structure and integrity (Huijberts MS et al 19 Feldman EL et al 
20).    
Diabetic Peripheral Neuropathy (DPN): 
Affects motor, sensory and autonomic nervous systems (Zochodone DW et 
al18, Feldman EL et al 20).    
Motor neuropathy: 
Intrinsic foot muscles get atrophied in motor neuropathy with subsequent 
development of anatomical changes in the foot and deformities. The balance 
between flexion and extension movements is lost with development of high 
pressure points. The   foot develops bony prominences that are abnormal. The 
superficial skin gradually breaks down and ulcer develops ( Carine Hm, et al 21 ). 
[5] 
 
Autonomic neuropathy: 
 Decreases sweat and sebaceous gland secretion. The overlying skin loses 
its moisture becomes dry and fissured. This increases susceptibility to cracks and 
thus infection ( Carine Hm, et al 21). 
Sensory neuropathy: 
Makes the patient insensitive to the triggering trauma and the injuries are 
left unnoticed. They are prone for repetitive trauma due to weight bearing and 
excessive pressure points during ambulation.   
Peripheral vascular changes: 
  Is one more added contributory factor in the development of foot 
ulcer. Persistent hyperglycemic state leads to abnormal endothelial cell and 
smooth muscle function in peripheral arteries (Zochodone DW et al 18).Decreased 
vasodilator Nitric oxide levels leads to vasoconstriction, increases the risk of 
plasma hypercoaguability, along with abnormal extracellular matrix of the vessel 
leads to narrowing of the arterial lumen (Carine Hm et al 21). 
The resultant ischemia ends in occlusive arterial disease in the lower limb 
with increased risk of ulcers (Paraskevas KI et al 22). 
Vascular changes leads to inadequate local blood flow which in turn favors 
infection and delay the wound healing.  The above factors along with 
[6] 
 
biomechanical changes in the foot contribute to the development and chronic 
nature of the ulcer.  
 
Diabetic Foot ulcers: 
 Halt at any stage of healing and remain in that stage for longer. The basic 
etiology prevents the anatomical and functional integrity back to normal unless 
interfered properly (Mostow EN et al23, Nomikos I N et al24).  
Persistent neutrophils and macrophages, release inflammatory cytokines 
and enzymes that damage cells (Snyder, Robert J et al25).Cytokines interfere with 
cell proliferation, wound closure and healing (Alleva, Renata et al26).keratinocytes 
fail to reepithelialize the wound and fibroblasts fail to produce adequate 
extracellular matrix proteins (Foy et al27). 
Reactive Oxygen Species (ROS) and myeloperoxidase enzyme released 
and damage DNA, lipids proteins, extracellular matrix (ECM).  
Growth factors formation is prevented or gets sequestered. Their normal 
metabolic functions are not carried out.  Proteases from various cells and bacteria 
degrade them excessively (Crovetti et al28) 
Proteolytic enzymes like elastase (Schönfelder et al 29) and matrix 
metalloproteinase are higher (Wysocki et al30).The released elastase inhibits 
proteases inhibitors (Edwards et al 31) and leads to more inflammatory reaction. It 
damage tissue collagen, fibronectin, proteoglycans and growth factors.  
[7] 
 
Excess matrix metalloproteinase released by leukocytes breaks down ECM 
molecules and favour degradation while minimizing deposition with imbalance 
between production and degradation (Ravanti L et al32, Vaalamo M et al33). 
Reactive oxygen species are generated and inhibit normal angiogenesis. They 
affect HIF-1 (Hypoxia inducible factor-1) stability, limiting endothelial progenitor 
cells mobilization from the bone marrow into circulation and wounds thus 
inhibiting angiogenesis which is a major component in wound healing (Botusan IR 
et al34). 
Disordered immune response thus prolongs the inflammation and breaks 
down the wound. Failure of reepithelialization makes the wound more prone to 
early infections and damage the tissues further leading to gangrene and limb 
amputation (Mustoe, Thomas et al35). 
Foot infections are common and sometimes remain the immediate cause for 
amputation. Furthermore the infections are commonly ignored by many patients 
and report to the hospital only with gangrene of foot and sepsis. At this point it 
becomes challenge to treat them with conventional management.   
Early diagnosis, prevention and management are essential to avoid this 
devastating complication. 
The following strategies are implemented for prevention of amputation rates 
in diabetic foot ulcer foot syndrome. 
1. Regular inspection of foot and foot wear 
[8] 
 
2. Preventive foot wears to high risk feet 
3. Multidiscipline approach to the management foot ulcer 
4. Early diagnosis of peripheral neuropathy and peripheral arterial disease  
5. Continuous follow up of patients 
Treatment: 
Diabetic foot ulcers are conventionally treated by off loading and 
debridement (Armstrong DG, Lavery LA et al36, Armstrong DG, Nguyen HC et al  
37).It is uncertain if these procedures can treat the cause of ulcers.  
Other treatment modalities like hyperbaric oxygen therapy is in use but 
presently have conflicting data regarding the efficacy of this therapy( Faglia E et 
al 38) and surgical therapies are also popular but costly.  
Few new adjunctive therapies like use of colony stimulating growth factors 
are under investigation. Some of these studies revealed nil results in resolution of 
infection in diabetic wounds (Cruciani M et al39) 
Use of non invasive methods like the electro physical modalities is under 
trial which have been used for many years. There are many studies that these can 
act as adjuvant therapy in promoting early healing in chronic non healing diabetic 
foot ulcers. Ultra sound therapy, laser therapy and electromagnetic field therapies 
are in wide use. 
 
  
[9] 
 
Pulsed electromagnetic field (PEMF) therapy: 
PEMF is becoming popular as an adjunct therapy for soft tissue healing. It 
is specifically designed such that it emits low frequency and low intensity 
electromagnetic fields to the tissues concerned and thus facilitates healing. It 
displays frequencies at the lower end of the electromagnetic spectrum.   
From many studies it is evident that electromagnetic fields when applied 
externally to soft tissues either interacts directly with the local wound currents or 
with cellular transduction signaling pathways (Lee RC et al 40) and thus play a role 
in re stimulation of wound that has retarded or arrested.  
  In the healing of soft tissue wounds the underlying concept in application 
of electromagnetic field therapy is that the induced electric fields have beneficial 
action at the level of cellular processes and functions involved in the wound repair.   
.  It is a safe and an easy procedure and feasible. Because of its non contact 
delivery to the tissues the chance of infection is prevented. 
The electromagnetic field therapy has influence at various levels of wound 
healing such as (Lee RC et al 40, Gentzkow GD et al41) 
1. Chemotaxis of inflammatory cells such as neutrophils and macrophages 
           2. Upregulation of various growth factor receptors 
           3. Proliferation of fibroblast and granulation tissue  
4. Epidermal cell migration  
5. Blood flow increase and edema reduction 
[10] 
 
It has been used for promoting tissue healing over the last few decades 
(Ieran et al 42). 
PEMF promotes growth factors activity and increase their levels in the 
blood, and found to increase the rate of nerve regeneration in animal and vitro 
studies (Ito H. & Bassett C.A. et al43). 
In human studies it is found to reduce pain, improves vibration sense, 
muscle activities, spinal cord motor excitability and restores nerve conductive 
dysfunction that is caused by diabetic polyneuropathy which is a major risk factor 
for developing diabetic foot ulcers (Musaev A.Vet al44).It Increases blood flow to 
the nerves and combat tissue hypoxia with no side effects reported (Webb, C. Y et 
al 45). 
As a result it is evident that the pulsed electromagnetic fields act as a 
potential, safe and an effective conservative management in promoting diabetic 
ulcer in clinical practice. 
Vascular Endothelial Growth Factor (VEGF): 
It is a signaling protein which induces vasculogenesis and angiogenesis. It 
was first isolated from ascitic proteins in 1983 and found to induce angiogenesis in 
cell culture. It was previously called as vascular permeability factor (Senger DR et 
al 46). 
  The VEGF family includes five subfamilies: VEGF-A, VEGF-B, VEGF-C 
and VEGF-D and placental growth factor (PGF).  
[11] 
 
VEGF-A is commonly called as vascular endothelial growth factor 
(Robinson CJ et al47).Its main function is to improve blood supply and 
oxygenation to the tissues. It also stimulates endothelial cell mitogenesis and cell 
migration, increases matrix metalloproteinase activity, chemotactic for 
macrophages and produces vasodilatation by releasing Nitric Oxide. 
Hypoxic cells stimulates the release of VEGF –A into circulation by  a 
transcription factor known  as hypoxia inducible factor .VEGF  bind to VEGF 
receptors on endothelial cells and leads to angiogenesis (Holmes et al48),which is a 
vital component of wound repair (Brem H et al 49) 
 
Diabetic foot ulcers and VEGF:  
Though various conditions favour expression of vascular endothelial 
growth factor in diabetic wounds it is actually defective. 
Induced full thickness excision wounds in animals showed initial increase 
but subsequent undetectable VEGF levels (Frank S et al50).Diabetic mice on 
induction of wounds with streptozotocin has showed defective synthesis of VEGF 
and other growth factors (Shukla A et al 51 ,Rivard A et al52). 
As diabetic foot ulcers has multiple physiological impairments to healing, 
including impaired innervations (Gibran NS et al53), impaired cellular migration 
(Brem H, Stojadinovic O et al 54)and inadequate angiogenesis(Cho CH et al 55)it is 
vital to introduce a therapy that interacts with all these cascades of events. It is 
hypothesized that electromagnetic stimulation influences the migratory, 
[12] 
 
proliferative and synthetic functions of fibroblasts and also result in increased 
expression of growth factors (Lee RC et al 40,Webb, C.Y et al45 Weiss DS et al 56 ). 
VEGF action in turn mediated by nitric oxide which leads to deposition of 
collagen reverts back endothelial dysfunction, improves nerve conduction and 
oxygen supply to the tissues (Witte MB et al 57). 
It was suggested that PEMF acts on Ca2+ calmodulin signaling mechanism 
leading to nitric oxide (NO) production (Markov MS, Wang S et al 58, Markov 
MS, Pilla AA et al, 1994 59 ,Markov MS, Pilla AA et al1997 60)and growth factor 
cascades involved in tissue healing.   
It is evident that PEMF works through NO cascade. This study focused on 
nature of healing in chronic diabetic foot ulcers following exposure to pulsed 
electromagnetic fields therapy with subsequent up regulation of vascular 
endothelial growth factor.  
 
 
 
 
 
 
 
 

[13] 
 
Review of literature 
2.1.1. Diabetes mellitus:  
Diabetes mellitus is characterized by hyperglycemia which occur either due 
to absolute deficiency of insulin or due to failure of insulin action on insulin 
receptors in the tissues.   
In the absence of insulin carbohydrate, protein and fat metabolic 
abnormalities result in the target tissues. Despite surrounded by high glucose the 
tissues cannot utilize glucose either due to insulin deficiency or due to insulin 
resistance.  
 
2.1.2. Classification: 
Old classification of diabetes is revised and new classification given by American 
Diabetes Association expert committee in 2003 and Diabetes is classified into two 
broad etiopathogenetic categories (American diabetes association 2012 et al61) 
 
Type 1 Diabetes mellitus (Insulin dependent diabetes or Juvenile diabetes): 
 It is associated with profound and absolute insulin deficiency due to β cell 
destruction or autoimmune disease of pancreas and requires insulin replacement 
therapy. It accounts for only 5-10% of diabetic population.  
 
[14] 
 
Type 2 Diabetes mellitus (Non Insulin Dependent Diabetes, Adult onset 
diabetes):  
The patients have a normal plasma insulin level and usually do not require 
insulin replacement therapy. They have relative insulin deficiency with insulin 
resistance. It accounts for about 90-95 % of diabetic population.  
Among the two, type II diabetes is more prevalent in older people above 
60yrs and is mostly undiagnosed until the late complications ensue due to lack of 
symptoms (Harris M.I.et al 62, Genuth S et al63). 
 
                                                                               
 
 
 
Fig-1. Prevalence of Types of Diabetes Mellitus 
 
2.1.3. Complications:   
Uncontrolled diabetes may result in acute life threatening complications 
like   “Diabetic ketoacidosis or the nonketotic hyperosmolar syndrome” (Genuth S 
et al63). 
Diabetes with associated Long-term complications includes: 
1.  Diabetic peripheral neuropathy and associated complications 
2.  Diabetic nephropathy with kidney failure 
[15] 
 
3. Diabetic retinopathy and associated complications  
4. Autonomic neuropathy with associated Cardiovascular, gastrointestinal, sexual 
dysfunction and genitourinary complications (Genuth S et al63). 
 
  Atherosclerosis, peripheral arterial diaease , cardiovascular, and 
cerebrovascular diseases are other common complications that occurs in diabetic 
patients. Metabolic X syndrome which is characterized by hypertension and 
lipoprotein metabolism irregularities are commonly seen in diabetes patients 
(American diabetes association 2012 et al61) 
 Diabetic foot ulcer is one of the common complications. It is the major 
component of the diabetic foot syndrome. It occurs in 15 % of all patients with 
diabetes.84 % of all diabetic –related lower –leg amputations are preceded by a 
diabetic foot ulcer (Brem, H et al64).  
 
2.1.4. Diabetic foot ulcer:  
An ulcer is defined as the “discontinuity in the epithelium” and a breach 
in the skin of foot including toes, heel, dorsum and the plantar aspect in diabetic 
patients is called as diabetic foot ulcer (Centers for Disease Control and 
Prevention 2003 65) 
 
 
[16] 
 
2.1.5. Risk factors:  
 Diabetic neuropathy  
 Diabetic nephropathy 
 Peripheral vascular disease 
 Ulcers or amputations of previous history  
 Smoking  
 Uncontrolled Diabetes” (Scott, G et al66) 
 
2.1.6. Pathophysiology:  
Diabetic peripheral neuropathy, peripheral vascular disease and 
accompanied biomechanical changes in the foot are the underlying major risk 
factors in diabetics that lead to foot ulcers (Mehmood K, Akhtar T et al67)  
There exists an interaction at various levels in the pathogenesis of 
neuropathy and vascular disease. The common basic pathogenesis is seen as 
follows. 
 
1. Polyol or Sorbitol pathway:  
Hyperglycemia increases the enzymes of sorbitol pathway (aldose 
reductase and sorbitol dehydrogenase).This reaction converts intracellular glucose 
into sorbitol and fructose. Elevated aldose sugars form advanced glycosylation end 
products which in turn leads to non enzymatic glycosylation of  intra or 
extracellular proteins. 
[17] 
 
AGEs cross-link with proteins like collagen, extracellular matrix proteins, 
slow down their turnover rate, and alter extracellular matrix composition and 
structure (Reiber, G.E. et al68) and this collagen becomes inflexible, easily break 
down.   
 
2. DAG/PKC Pathway:  
Increased triose phosphate metabolites leads to increased second messenger 
diacylglycerol thus  activates protein kinase C (PKC) which alters transcription of 
genes for fibronectin, type IV collagen, contractile proteins, and extracellular 
matrix proteins in endothelial cells and neurons.  
Arachidonate in DAG is a substrate for synthesis of ecosanoids  
(prostaglandins,prostacyclins,thromoxanes and leukotriens) which  are potent 
vasoconstrictors. 
 
3. Oxidative Stress:  
Decreased NADPH/NADP leads to alteration in redox state and  the ability 
to deal with oxidative stress is decreased. 
Increased aldose sugars alter redox potential, increases cellular osmolality.  
Hyperglycemia induces mitochondrial dysfunction. Glucose and other 
metabolites undergo auto oxidation. Advanced glycation end products generate 
reactive oxygen species and increase oxidative stress. Resulting Oxidative stress 
leads to endothelial dysfunction and diminish nitric oxide synthesis and release.   
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Fig 2: PATHOGENESIS OF NEUROPATHY 
Nitric oxide synthase inhibitors get accumulated by polyyol flux pathway 
and results in reduced nitric oxide synthesis ( Goldin, A et al69).Nitric Oxide is 
important for  normal blood flow and it maintains the diameter of the blood 
vessel(Obayashi, K et al70, Duda, D et al 71,Dinh T et al72).Therefore the absence of 
NO results in  vasoconstriction which leads to occlusion of endoneural capillaries 
and nerve hypoxia ensues.  
Diabetic poly neuropathy: Microangiopathy of the vaso nervosum, 
structural damage, axonal atrophy and axonal loss results in diabetic poly 
neuropathy(Brownlee M et al73)Accumulation of sorbitol and fructose in Schwann 
cells lead to decreased nerve myoinositol, reduced Na-K ATPase activity, 
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impaired axonal transport, abnormal action potential propagation and breakdown 
of nerve structure.  All the three motor, sensory and autonomic neurons are 
affected. 
 
 
                        
 
 
 
                                    Fig.3.Pathogenesis of foot ulcer 
Sensory neuropathy:  
It is the key element in the development of ulcers (Reiber, G.E. et al68). 
Impaired sensation prevents withdrawl of foot from any painful stimuli and thus 
easily get injured while walking with bare footed (Boulton, A Jet al74 ,Bus, S.A et 
al75). 
 
Motor neuropathy:  
Damage to motor neurons results in weakness, wasting and atrophy of 
intrinsic and interosseous muscles in the foot. A functional and structural change 
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in the foot ensues, with resultant loss of balanced gait and deformities in the 
affected foot (Feldman EL et al20)  
 
Various structural and biomechanical abnormalities are (Fryckberger RG et 
al76, Lawrence L, et al77)  
1.  Clawing of toes 
2. Cavus Foot deformity:  
The normal foot shape is convex as the longitudinal medial arch extends 
between first metatorsophalyngeal joint head and the calcaneus bone. Diabetics   
have high arch with resultant irregular distribution of pressure loads while walking 
and which leads to callosities in the foot.  
 
3. Equinus Deformity: 
  Achilles tendon shortening with collapse of the plantar fascia facilitates 
abduction or adduction equinus deformity.   
 
4. Rigid 1st toe: 
  The first MTP joint harden and fail to dorsiflex. The plantar surface 
undergoes excessive weight forces and results in callus.  
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5. Stiffness of the joint:  
Abnormal glycosylated collagen in the joints leads to restricted mobility 
with periarticular tissues thickening. Foot abnormalities develop. Plantar flexion is 
limited due to excessive pressure points and equinus foot deformity. Talar, 
subtalar, MTPJoints are involved.  
The normal feet while making contact with the ground absorb any shocks 
that develop on walking. This is impaired in diabetic patients due to the above 
mentioned changes .Bony prominences develop underneath the foot pushing the 
fibro fatty shock-absorbing tissues forward, exposing the condyles of the 
metatarsal heads (Contemporary management of the diabetic foot78, Lyons et al79)   
Plantar pressure distributing capacity is reduced and favours high foot 
pressures in diabetics. 
 Normal foot arch support is lost in these patients during weight bearing. 
Soft tissue thickening at metatarsal heads contributes to high pressure (Cavanagh, 
P. R. et al80) this makes these ulcers to be present more commonly underneath 
metatarsal heads (Gefen, A. et al81).   
A normal foot usually prevents the development of ulcers by redistributing 
the load equally over the entire surface -the forefoot, middle foot and rear foot”. In 
diabetics, because of architectural changes in the foot this capacity is reduced. 
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Fig-4. Foot deformities 
Picture-A: shows clawing in the toe with plantar and dorsal aspects receiving more 
pressure. 
Picture B: shows Charcot arthropathy in which the plantar aspect of mid foot 
received more pressure. 
 
6. Nail Deformity: 
In grown nails are commonly seen in diabetics due to nail thickening , 
atrophy of the  nail plate  with convex  shaped deformity that give pressure on the 
ridge tissues. Due to inflammation and pressure the nail flange forms a callus and 
susceptible to trauma, infection and ulceration ( Fryckberger RG et al 76 ,Lawrence 
L, et al77). 
 
Plantar foot pad integrity:   
Plantar foot pad located under the ball of the foot, beneath metatarsal heads, 
calcaneous or heel and provides in built cushion mechanism. Normally metatarsal 
[23] 
 
heads and the calcaneous bear the peak load on weight bearing and hence benefit 
from the most of the protective, cushioning provided by the plantar fat pad 
((Gefen, A. et al81).Where there is clawing or retraction of the lesser digits, the 
plantar fat pad under the metatarsal heads migrates and is displaced anteriorly  
leading to ulcer. 
     
Fig-5. Foot fat pad integrity 
 
Autonomic neuropathy:  
Leads to impaired blood flow, diminished sweat, loss of overlying skin 
moisture finally ends in dry, cracked or fissured skin with fractures and callosities 
around the foot injury. 
Callus or Callosities:  
These are focal areas of increased pressure at weight bearing areas and acts 
as a foreign body exerting a concentrated pressure on underlying tissues thus are 
the potential sites for the ulcers to develop. 
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 There is strong relationship between callus and other hyperkeratotic skin 
lesions and diabetic foot ulcers (Fernando. D. J et al82)  
They are more commonly seen in the rim of heel, plantar medial and first 
MTP joint and there is increased susceptibility to tears with subsequent 
development of infection and cellulitis (Brem, H., Sheehan, P et al83). 
Peripheral Vascular Disease: 
Persistent hyperglycemia results in abnormal Endothelial cell function and 
smooth cell abnormalities in the  vessels(Zochodone DW et al18) 
 Endothelium-derived vasodilators (NO) decreased leading to 
vasoconstriction. Diabetics have hypercoagulability status due to increased 
thromoxane A2.   
  
Fig-6. Hypercoagulable state in diabetes mellitus  
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Macro vascular and micro vascular changes lead to decreased capillary 
blood flow in the nutrient vessel and results in ischemia. Microvasular changes 
include capillary size reduction, basement membrane thickening and AV 
shunting61 with reduced capillary recruitment. 
Inadequate perfusion in the tissues leads to defective auto regulation of the 
vessels permeability changes and chemotaxis of leucocytes (Dinh T et al72) 
Macrovascular changes include atherosclerosis, occlusive narrowing of the 
vessel with resultant reduction in nutrient blood flow and ischemia. There is risk 
of stenosis in the arterial lumen due to changes in the vascular extracellular matrix 
(Fryckberger RG et al 76).Tibial and peroneal arteries of the calf are commonly 
affected with subsequent occlusion.  
The sympathetic blood flow which controls arteriovenous shunts is 
reduced. Decreased arteriovenous pressure over capillaries reduces flow in the 
nutritive vessels and leads to impaired skin capillary circulation in the toes.  
Thus skin integrity is lost, becomes dry and portal of entry to bacteria. 
Impaired micro and macro vascular circulation lowers oxygenation in the wound 
(Nazimek-siewniak, B et al84) and contributes to nerve hypoxia (Malik, R. A. et 
al85). 
In addition to major contribution of neuropathy and vascular disease 
difficulty in wound healing is an important and independent component.  
           
 
[26] 
 
 
 
 
 
 
 
 
 
Fig-7.Pathogenesis of Chronic Ulcer 
              
2.1.7. Diabetic ulcer a chronic ulcer:   
Acute wounds normally heal by stage of inflammation, proliferation and 
remodeling (Shai. A. & Maibach. H. I. et al86).Blood vessels constrict to arrest 
bleeding and release inflammatory cells that initiate inflammation followed by 
vasodilatation which increases vascular permeability, recruits neutrophils and 
macrophages to the wound site. 
These cells fight against pathogenic organisms, secrete various growth factors 
and cytokines .The released growth factors and cytokines recruit fibroblasts, 
epithelial cells and keratinocytes to the wound area. Angiogenesis occurs by 
endothelial proliferation. 
Wound heals by formation of granulation tissue, collagen deposition and 
epithelialization.There is sequential and timely healing with overall restoration of 
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functional and anatomical integrity. Collagen type 3 is converted into more stable 
collagen type 1 which is arranged in orderly manner and results in scar formation. 
Tensile strength increased with precise balance between collagen deposition and 
degradation (Shai. A. & Maibach. H. I. et al86). 
Diabetic ulcer is characterized by Retarded Wound Healing  
 Inadequate blood supply to the tissues with resultant hypoxia interferes 
with proper wound healing and converts it into a chronic ulcer.  
Muscle atrophy, bone defects, deformed foot and gait changes that leads to 
new pressure areas with repetitive trauma and recurrent infection leads to 
development of chronic ulcers. They become refractory to heeling. 
A chronic ulcer is the one that takes more than three months to heel.   
Less vascular endothelial growth factor (VEGF) is released from macrophages. 
Matrix metalloproteases (MMPs) are excessively activated and MMP2, MMP9 
over expression (Wysocki et al 30). Metalloproteinase-2 inhibitors in the tissues are 
very low thus extracellular matrix and growth factors are degraded excessively.  
MMPs also generate antiangiogenic factors with reduced vascularity and 
angiogenesis which is characteristic of DFUs.  
 
2.1.8. Diabetic foot infections: 
 Hyperglycemia act as culture media and increases the virulence of 
microorganisms. Diabetic foot infections present as simple as paronychia, to 
severe infections like onychomycosis, cellulitis etc. 
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2.1.9. Classification of diabetic ulcers:  
Wagner Ulcer Classification system is based on depth of the wound and the 
necrotic tissue extent (Wagner FW Jr et al86). 
                             Wagner ulcer classification system 
GRADE                                        LESION 
1 Superficial diabetic ulcer 
2 
Ulcer extension involving ligament, tendon, joint capsule, or 
fascia with no abscess or osteomyelitis 
3 Deep ulcer with abscess or osteomyelitis  
4 Gangrene to portion of forefoot 
5 Extensive gangrene of foot 
             
The University of Texas system is based on depth of the ulcer, presence or 
absence of infection and ischemia (Oyibo SO, Jude EBet al87).   
                 University of texas wound classification system 
STAGES DESCRIPTION 
Stage A  No infection or ischemia 
Stage B Infection present 
Stage C Ischemia present 
Stage D Infection and ischemia present 
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Grading Description 
Grade 0 Epithelialized wound 
Grade 1 Superficial wound 
Grade 2 Wound penetrates to tendon or capsule 
Grade 3 Wound penetrates to bone or joint 
 
Higher grade and stages fail to heal unless intervened like vascular repair or 
amputation ( Frykberg RG et al88 ) 
 
2.1.10. Treatment of diabetic Ulcer: 
Reverting back the blood sugar is the basis in the management thus 
preventing the related complications. The treatment depends upon the severity of 
the ulcer and ischemic status. The primary interventions to be carried are (Aguilar 
F, Steed, D. L. et al89,90). 
1. Debridement of necrotic tissue and surrounding edges  
2. Reduction in off loading and Foot rest ---orthotics  
3. Antibiotics to get rid of infection 
4. Wound care.  
1. Debridement:   
Necrotic and non viable tissue with thick callus is removed without fail 
otherwise this tissue fails to regenerate and interfere with healthy tissue formation.   
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Superficial wounds without bone or tendon involvement treated with 
enzymatic debridement or autolytic debridement. Early removal of devitalized 
tissue and enhancement in healing process are the advantages. 
Autolytic debridement occurs naturally and wound exudates contain 
leucocytes and autolytic enzymes. Though slow, this process removes devitalized 
tissue from the wounds.   
Debridement begins healing process by activating platelets, keratinocytes 
migration and   growth factors release (D. L. et al90). 
 
2.  Off-loading:  
Off-loading is an essential component of healing of foot ulcers as they are 
common to occur in high pressure areas of foot with sensory loss. There is 
retardation of healing and increased risk for complications if pressure is not 
reduced.  Total contact casting is an effective off-loading technique for treatment 
of neuropathic wounds (D. L. et al90). 
In total contact cast, the cast is minimally padded and molded carefully to 
the shape of the foot. These special casts redistribute weight off the ulcer site and 
allow patients to walk while the ulcer heals (Hartsell, H. D.et al91) 
Though successful this method is not advisable to all diabetic foot ulcers, 
also it requires experienced, specially trained technicians because inappropriate 
application of the cast may worsens the ulcer and infection.  
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3. Treatment of Infection: 
Cellulitis,osteomyelitis and other deep tissue infections complicate diabetic 
ulcers if not treated ends in septicemia and death. 
Wound culture for   bacteriological diagnosis is to be done, topical 
antibiotics to be started empirically and   x-rays to be taken to rule out the 
possibility of abscess or osteomyelitis. Parenteral antibiotics are used for 
infections in deep soft tissue infections, cellulitis and those with excess drainage.  
 
4. Wound care:  
Clean dressing with proper humidity and environment lead to recruitment 
of epithelial cells and growth factors and protects from dehydration and death. It 
hastens angiogenesis.  
 
Newer Interventions: 
1. Biological Therapy or cell therapy:  
Diabetic foot ulcers are characterized by defective angiogenesis and growth 
factors. Cell therapy or biological therapy by releasing growth factors by 
increasing cytokines and extracellular matrix proteins and by promoting 
angiogenesis can be treatment option in some cases.  
It has consists of biological layers of which an allogenic human 
keratinocytes on overlying allogenic human fibroblast layer suspended within a 
collagen matrix (Veves, A et al 92). 
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For those ulcers with resistant to standard therapy this treatment has proven 
effective. Collagen, growth factors and matrix proteins which favour wound 
healing and epithelialization of the tissue synthesized by fibroblasts (Gath, H. J. et 
al93).The substances secreted by keratinocytes stimulate target genes, which 
control various cellular activation cycles that are responsible for the wound 
healing process. Though easy to apply as outpatient, inpatient and nursing home 
setups, they need several applications due to lesser half life of just 6 weeks. 
 
2. Growth Factors: 
   By recombinant DNA technology synthetic growth factors are generated.    
They initiate wound repair by various cellular mechanisms like proliferation of 
and chemo taxis of the cells, new vessel formation, growth factors and other 
protein expression, and enzymatic production. They act within the wound and 
send signals to the target cells (Brem, H., Young, J et al94). 
They can be applied topically and accelerate healing of the wounds, 
stimulates granulation tissue and enhance epithelialization (Steed, D. L. et al90) 
Usually they are much effective in healing if used as single or isolated 
forms as they influence different types of cells as platelet derived growth factor.  
Recombinant human PDGF-BB is one of the best examples which have 
similar biological activity to that of natural PDGF. It promotes wound repair 
process by the recruitment and proliferation of cells (Embil, J. M. et al95).It is 
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found to be safe and pharmacologically proven active treatment for chronic lower 
extremity diabetic ulcers.  
They are applied as a thin layer to the wound with a tongue depressor and 
covering it with a moistened saline gauze dressing and then rinsed off gently after 
12 hours with changing the dressing. The procedure is repeated every 12-hours 
(Milington J.T.  et al 96).But further trials are needed to estimate the required 
concentration for optimal wound healing.  
 
3. Negative Pressure Wound Therapy 
  This is a recent technique which utilizes a vacuum- assisted closure device    
refractory ulcers, unsatisfactorily healed ulcers, complex ulcers, and recurrent post 
operative or post amputation ulcers. It is found to result in rapid healing when 
compared to standard treatment (Armstrong, D. G.et al97).Ambulating patients 
wear these units around their waist and free movements are allowed to perform 
day to day activities.  
 
4. Reconstructive mode of therapies: 
Plastic surgeries are of use if the above explained approaches failed to 
reduce in the ulcer area more than 10 percent even after a 2 months period.   
They high are presented with complications such as osteomyelitis and 
required revascularization before reconstruction in 52% and 42 percent of the 
patients respectively (Attinger, C. E. et al98).  
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5. Gene therapy: 
This is an expensive procedure and it focuses on growth factor production 
as well as inhibits various proteases that inhibit growth factors. 
Education of every professional who treat and the patient is utmost important 
thing to prevent and detect any complications of diabetes mellitus. “Updated 
medical information needs to cover all news about nutrition, hypertension, obesity 
and dyslipidemia (metabolic syndrome)”.  
 
Ulcer recurrence: 
 Previous ulcer or amputation usually associated with recurrent foot ulcers 
and about “60% of diabetic patients with a history of foot ulcer may develop 
another ulcer within a year of healing” ulcers (Luca DP et al99).The persistence of 
risk factors, fragile skin and soft tissues breaks easily at healed site are the reasons. 
Residual deformities formed at the areas of previous amputation area increase 
plantar pressure and leads to ulcer. Any previous surgery alters biomechanics of 
the foot results in gait abnormalities and loss of balance. New ulcers develop in 
the future at the high pressure areas.  
Failure of surgical and non surgical treatment will end up in amputations. 
Even with best available treatment the outcome is unsatisfactory.    
Many adjunctive therapies are also popular, among them Hyper Baric 
Oxygen Therapy most commonly used.  Though earlier studies have showed a 
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beneficial effect of HBOT universal success is not reported (Kalani M et al 100).It 
is also associated with complications like middle ear barotrauma and sinus pain.  
Therefore a search of effective and new method to treat diabetic foot ulcers 
is needed. The use of physical modality is an alternative treatment approach for 
promoting healing in diabetic foot ulcers. 
 
2.2.1. Electro physical therapy in diabetic foot ulcers: 
Electro physical therapy consists of a variety of physical modalities 
ranging from electrical stimulation to the use of sound waves like ultra sound, 
laser to electromagnetic energy (Pope, G. D. et al 101) .These modalities have been 
used to promote repair wounds, and fibroblast activity enhanced (Webb & Dyson, 
M.et al102) and angiogenesis (Goldman, R.et al103).There are many ongoing clinical 
studies for the use of electro physical modalities in diabetic wounds. Many studies 
were done on animal and in vitro studies. But it is uncertain whether these 
treatments have effects in diabetic ulcers (Gal, P.et al104).  
 
2.2. 2.Pulsed electromagnetic field therapy in diabetic foot ulcers:  
 Use of magnetic fields as therapy in disease conditions has a long history. 
First  scientific evidence is given in the book “ De Magnete” written by William 
Gilbert during 1600 who was a personnel physician of the English Queen( Gilbert, 
W,  et al 105).After second world war II, Japan introduced  contemporary 
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management of various diseases with magnetic and electromagnetic fields which 
is moved to Europe. 
Todorov wrote the first book on electromagnetic therapy and its 
applications in various conditions (Todorov, N.et al106).In seventies 
“C.A.L.Bassett” and team proposed  a modern  approach using  low frequency 
signal to treat delayed bone fractures (Basset ,C.A.L.et al 107 ), and got FDA 
approval for its use.  Now its use is accepted in various common healing processes 
worldwide.   
Electromagnetic radiation is broadly classified into ionizing and non-
ionizing radiation. The study of interaction between non ionizing electromagnetic 
fields and biological systems is called as Bioelectromagnetics. 
Magnetic field therapy included electromagnetic fields consists of six 
varieties   that are developed and used in vast number of countries throughout the 
world (Markov, M.S. (2004a)et al108). 
 Static/ permanent magnetic fields created by permanent magnets as well as 
by passing direct current (DC) through a coil. 
 Low frequency sine wave electromagnetic fields use 60 Hz or 50 Hz. 
 Pulsed electromagnetic fields are low frequency  fields with specific shapes 
and amplitudes 
 Pulsed radiofrequency uses the radiofrequency range 13.76, 27.12. and 
40.68 MHz 
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 Tran cranial magnetic /electric stimulation is a method of treatment of 
selected areas of the brain with short but intensive magnetic pulses. 
 Millimeter waves have very high frequency range of 30-100 GHz.   
PEMF has special design and it direct magnetic fields in to the tissues 
concerned and promote healing. They display broad frequencies in 
electromagnetic spectrum ranging from 6 Hz up to 500 Hz (C.A. Bassett,et al109) . 
Use of very low frequency fields are non-ionizing and non heating or 
minimal heating to tissues (B.Rubik ,et al110).The shapes of PEMF wave forms are 
either asymmetric, biphasic, quasi rectangular or quasitriangular in shape but most 
are sinusoidal. Specific type produces specific effect; pulsed one has more efficacy 
than continuous fields (D.H. Trock et al111). 
 
PEMF acts on biological systems by two ways:  
1. Capacitive or direct coupling in which the opposite electrodes applied 
directly to skin surface of interest (D.H. Trock et al111). 
2. Inductive or indirect coupling in which time-varying electric fields are 
induced  at the concerned  repair site by the  application of  a time-varying 
magnetic field through single  or two electrical coils. They are not with skin 
contact.  
The field parameters are determined by the frequency characteristics of the 
magnetic field applied and also the electrical properties of the target tissue.  
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2.2.3. Electromagnetic field generation: 
 “The time –changing magnetic field of the PEMF induces an electric field 
(Faraday’s law of induction), which in turn produces a current in the body’s 
conductive tissue” (D.H. Trock et al111,G.C. Traina et al112)  
“Faraday law of induction states that a changing magnetic field produces an 
electric field and if this electric field is in a conducting medium, there will be an 
electric current flow. This induced voltage is proportional to the time- rate of 
change of the magnetic field” (Sanker Narayananet al 113).It means that the 
potential difference (or voltage, V) between two ends of a wire, placed in a 
changing magnetic field is V= -d /dt   where the time-rate of change is flux 
=d /dt.  
The electric field induced via a time-varying magnetic field waveform is 
directly related to the electrical characteristics of the coil employed and the current 
waveform applied to the coil.  
Induced electromotive force (emf) is proportional to the rate of change of 
current in the coil (dIcoil/dt) which produces the shape of the induced electric 
field.  
Faraday’s Law of Induction and Maxwell’s equations explains the 
generation of electromagnetic field (EMF).A static electric field (EF) is generated 
by a static charged particle. The EF (or E component of an EMF) exists whenever 
charge is present. Its strength is measured in volts per meter [V/m].  
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An EF of 1 V/m is represented by a potential difference of 1 V existing 
between two points that are 1 m apart. The V/m is primarily used to express the 
intensity of the EMF.  
MF (or M component of an EM field) arises from the current flow. Its flux 
density is measured in tesla (T) in the International System (SI), and in gauss (G) 
which is the former CGS system of units (1 G = 10-4 T or 1 T = 10 milligauss).  
A flux density of 1 G represents 1 Maxwell/cm2. The tesla (or Gauss) is 
mainly used to denote the flux density (intensity) produced by MFs. Both electric 
fields (EFs) and magnetic fields (MFs) are generated if a charged particle moves at 
a constant velocity.  
EMFs are generated when a charged particle is accelerated. Most often this 
acceleration takes place in the form of an oscillation, therefore electric and MFs 
often oscillate. Change in the electric field (EF) creates a MF, and any change in 
the MF creates an EF.  
This interaction suggests the higher the frequency of oscillation, the more 
the electric and MFs are mutually coupled. EMF devices include solenoids, Trans 
cutaneous Electrical Nerve Stimulation (TENS), and Helmholtz coils.  
The magnetic energy produced is as little as that of the Earth’s magnetic 
field to more than 10,000 times as powerful.  
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2.2.4. The mechanism of action of pulsed electromagnetic field on wound 
healing: 
  Based on a number of cell and animal studies it was suggested that PEMF 
acts on Ca2+ calmodulin signaling mechanism leading to nitric oxide (NO) 
production (Strauch, B. et al114) and growth factor cascades involved in tissue 
healing.   
PEMFs modulate the calcium-binding kinetics to calmodulin. 
Calcium/calmodulin (Ca/CaM) then activates nitric oxide synthase (NOS) in 
several different isoforms.  
When injury occurs, large amounts of nitric oxide are produced by long-
lived inducible nitric oxide synthase (iNOS). In this cascade, tissue levels of nitric 
oxide persist and the prolonged presence of this free radical is proinflammatory, 
which accounts for the leaky blood vessels associated with pain and swelling.  
In contrast, the endothelial and neuronal nitric oxide synthase isoforms 
(respectively eNOS and nNOS) produce nitric oxide in short bursts that can 
immediately relax blood and lymph vessels.  
These short bursts of nitric oxide also lead to the production of cyclic 
guanosine monophosphate (cGMP), which in turn drives growth factor production.    
iNOS is not dependent on CaM, while the constitutive or cNOS (eNOS or nNOS) 
cascade is dependent on the binding of Ca/CaM.  
Therapies that could accelerate Ca/CaM binding, therefore, should impact 
all phases of tissue repair, from initial pain and swelling to blood vessel growth, 
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tissue regeneration, and remodeling. As shown in the following diagram, this 
mechanism has been proposed as a working model for PEMF therapeutics. 
 
 
 
 
 
 
 
 
                                           Fig-8.PEMF Mechanism 
It is known that NO is a critical molecular signal and mediator for normal 
wound healing (Boykin, J. V.et al115,Filippin, L. I.,et al116) NO deficiency has been 
established as an important mechanism responsible for poor healing in diabetic 
foot ulcer patient.  
Co-cultures of human dermal fibroblast and human epidermal keratinocytes 
exposed to PEMF demonstrated an up- regulation of gene families involved in 
tissue repair. These include matrix metalloproteinase (MMPs) and tissue inhibitor 
of metalloproteinase (TIMP’s), and cytokines - interleukin (IL)-related genes, 
interferon (INF)-related genes, and tumor necrosis factor (TNF)-related genes. 
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2.2.5. Biophysical consideration of EMF therapeutics: The induced current at 
the wound site leads to several electrochemical interactions at cell surfaces,  
 Non specific electrostatic interactions of  water dipoles and hydrated (or 
partially hydrated) ions at the lipid bilayer/aqueous interface of a cell 
membrane and  make all cell membranes a capacitor( Pilla, A. A.,et al117).  
 Voltage dependent ion/ligand binding (Plonsey R, et118) ion or dipole 
competes effectively with water dipoles and hydrated ions at specific 
membrane sites, which modulate a downstream cascade. 
The electrochemical pathways involved in the transduction of an exogenous 
EMF signal  operates similar to the initial gating process involved in the 
production of the action potential via membrane depolarization( Pilla, A. A.et 
al119). 
A non thermal EMF has direct affect ion binding and/or transport and 
influence the cascade of biological processes related to tissue growth and repair 
(Lee, R. C.,et al 120). 
Most wound studies involve arterial or venous skin ulcers, diabetic ulcers, 
pressure ulcers, and surgical and burn wounds. Since cells involved in wound 
repair are electrically charged, some endogenous EMF signals may facilitate 
cellular migration to the wound area (Markov, M. S., Hazlewood,et al121) thereby 
restoring normal electrostatic and metabolic conditions.  
Because the main goal of any therapy is to restore normal function to the 
organism, electric, magnetic, or electromagnetic modalities appear suitable to 
[43] 
 
compensate the injury currents. PEMF have also been beneficial in treatment of 
chronic pain associated with connective tissue like cartilage, tendon, ligaments, 
and bone injury and joint-associated soft tissue injury .Growth factor activation of 
the Na-K ATPase enzyme in fibroblasts (Kaplan JG.et al122).Ca2+ regulation, via 
CaM, of the cell cycle; Ca2+ dependent adenylate cyclase activation in 
macrophages Whifield JFet al123).Ca/CaM regulation of growth factor and other 
cytokine release (Means AR et al 124). 
EMF could also modulate the distribution of protein and lipid domains in 
the membrane bilayer, as well as conformational changes in lipid-protein 
associations by altering the kinetics of binding.  
Ion/ligand binding represents a coupling or transduction mechanism for 
exogenous electromagnetic fields at biological surfaces and junctions, which can 
be used to quantitatively and predictively configure bioeffective EMF waveforms.  
Cellular gap junctions provide pathways for ions and molecular 
intercellular communication (Sheridan JD, et al125).and provide ionic coupling and 
metabolic cooperation which is crucial for growth control and tissue repair. The 
role of cooperative organization in the EMF sensitivity of biological systems has 
been qualitatively considered (Adey WR.et al126).Functional modification of gap 
junctions by modulated microwave fields, as well as EMF signals has been 
reported (Fletcher WH et al 127).   
  In July of 2002, the accumulated background of information led the U.S. 
Centers for Medicare and Medicaid Services to finally approve coverage for 
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electrical stimulation as adjunctive therapy for stage III and stage IV pressure 
ulcers, arterial ulcers, diabetic ulcers, and venous ulcers, providing that 
improvement had not occurred after 30 days of standard wound treatment”( PJ 
Rosch,et al128). 
The interaction between various types of cells (vascular, epidermal and 
dermal cells), growth factors, cytokines, chemokines, adhesion molecules, nitric 
oxide, trace elements and proteases usually determine the outcome of normal 
healing process. The electromagnetic field therapy targets these interactions. 
Hyperglycemia and disturbances in insulin signaling affect the glucose utilization 
in keratinocytes, thereby its differentiation and proliferation (Spravchikov N, et 
al129).  
Also, reduced nitric oxide synthesis seen in diabetes retards the functioning 
of keratinocytes and fibroblasts, essential for normal wound healing resulting in 
impaired wound healing (Shi HP et al130).Decreased concentration of platelet 
activating factor in wound is also associated with impaired healing. Although, 
many causes for impaired wound healing have been suggested, vascularity of 
tissues seems to be most important, which is targeted by the PEMF therapy. 
 
PEMF therapy effect on microvascularity:  
 PEMF accelerates the endothelial cell growth rate (Yen-Patton GP et al 131). 
Sinusoidal PEMF was shown to improve the microcirculation, fibroblast 
proliferation and differentiation (Nikolaev AV, et al132, Loschinger M et al 133 
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Hinsenkamp M, et al134).The underlying mechanism of this has been suggested as 
immediate and temporary rise in cAMP-dependent protein kinase activity (Thumm 
S, et al135).The improvement in blood flow is found mainly small arteries and 
arterioles in the wound site (Matsuda T et al 136) . 
 
F. Influence on cytokine production: 
Exogenously applied EMF affects cell signaling and cytokine production. 
In a model studying osteoarthritis, EMF showed statistically significant 
improvement in stimulating transforming growth factor beta (TGF-β)( Ciombor 
D,et al137) 
TGF-β upregulate gene expression of cartilage core protein and MMP 
inhibitors Matrix metalloproteases of (MMP) and IL-1 are down regulated by 
TGF-β and it was suggested that EMF influences homeostasis of cartilage by 
stimulating TGF-β. Also some studies show that cytokines IL-1β and TNF-α are 
decreased and IL-10 is increased by PEMF (Gómez-Ochoa et al 138).  
 
Some of the effects of PEMF: 
1. Increased number of chondrocytes, 75Hz, 2.3 mT   (Richards TL et al139) 
2. Influence proliferation of osteoblasts, 15 Hz, 0.1 mT . (Mattei MD et al140) 
3. Osteoclasts shows a decreased production of osteoclasts, 7.5 Hz, 300µs  
4. Adenosine receptors are saturated with neutrophils and decreases cytokine 
cascades75 Hz, 0.2 mT  to 3.5 MT (Gomez-Ochoa I et al138) 
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5. Mononuclear shows a significant increase in IL-1β and TNFα- proinflammatory 
cytokines, 50Hz, 2.25mT (Farndale R et al141) 
6. Fibroblasts show cAMP reduction and collagen proliferation leads to increased 
proliferation of collagen cell, 15Hz, with a pulse of 4.8 ms (Delle Monache S. et al 
142) 
7. Endothelial cells shows a increased count leading to angiogenesis, 50 Hz, 1 me 
(Pipitone N et al143) 
2.3.1. “Vascular endothelial growth factor”:  
Vessels are formed mainly by two consequent mechanisms namely 
vasculogenesis and angiogenesis.  
 
Vasculogenesis : 
Blood vessels are synthesized denovo, from stem cells of mesodermal 
origin, hemangioblasts that in turn gives rise into primordial hematopoietic cells 
and endothelial cells called angioblasts.  
Angiogenesis, development of new capillaries from preexisting vessels is a 
highly regulated process, playing a major role in physiological processes like 
embryological ovulation, menstruation and wound healing (Carmeliet P.et al 144) 
Disproportionate angiogenesis is seen in tumors and some other systemic 
disorders. VEGF receptors are expressed in the cells responsible for angiogenesis, 
implying the role of VEGF in blood vessel and capillaries formation. 
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2.3.2. Structure of VEGF: 
VEGF is a homodimer, glycoprotein in nature closely resembling platelet 
derived growth factor (PDGF) in its structure (Keck PJet al145)  
Various forms of VEGF isolated till date includes VEGF-A, VEGF-B, 
VEGF-C, VEGF-D and placenta growth factor. VEGF is usually referred to as 
VEGF-A, primarily referred to as Vascular Permeability Factor VPF, owing to its 
nature of inducing vascular permeability. 
 
Mechanism of action of VEGF:   
The actions of VEGF are mediated by tyrosine kinases, namely VEGFR-1 
VEGFR-2 and VEGFR-3.  The vasculogenic and angiogenic activity of VEGF 
seen in various physiological processes is mediated by VEGFR-2, primarily found 
in endothelial cells (Robbins and cotran et al 146). 
 VEGF is produced by cells participating in wound healing processes like 
endothelial cells, fibroblasts, smooth muscle cells. Furthermore, hypoxia, 
transforming growth factor α and β and Platelet derived growth factor may induce 
the VEGF production from these cells.  
The VEGF has versatile function, acting in a paracrine fashion, affecting 
the endothelial cells and skin microvasculature. It also plays a role as an 
endothelial cell mitogen, a chemotactic agent( Ferrara N et al 147) and wound 
healing process, mainly angiogenesis, epithelization and collagen deposition 
(Stojadinovic OKA et al 148) 
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Mechanism of angiogenesis: 
Angiogenesis, otherwise termed neovascularization, involves the 
recruitment of progenitor cells of endothelium from bone marrow which cause the 
extensive branching off and extension of pre-existing blood vessels. 
 
Process of angiogenesis from pre- existing vessels: 
 Nitric Oxide mediated vasodilation of the parent vessel  
 Degradation of  parent vessel basement membrane by matrix 
metalloproteinase  (MPS) 
 Disruption of cellular contacts between adjacent endothelial cells by 
plasminogen activator  
 Endothelial cells migration towards the angiogenic stimuli  
 Proliferation of migrated endothelial cells, followed by the maturation of 
endothelial cells  
 Migration of Pericytes and vascular smooth muscle cells to form the mature 
blood vessel (Robbins and cotran et al 146). 
                                                                                                  
 
 
 
                                                                                                       
Fig.9. Angiogenesis from pre-existing vessels 
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2.  Process of Angiogenesis from endothelial precursor cells (EPCs): 
  Mobilization of endothelial precursor cells from the bone marrow  
 Migration  of  EPCs to injury area  
 Differentiation, maturation of (EPCs) and formation of mature capillary 
plexus by forming links with previously existing vessels. 
 
Fig.10. Angiogenesis by mobilization of EPCs from the bone marrow 
 
 
 
 
 
 
 
Fig.11. Effect of hypoxia on vasculogenesis  
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2.3.6. Role of VEGF in angiogenic cascade mechanism: 
VEGF has multiple roles in wound healing such as new vessel formation 
dilation of blood vessel, degradation of basement membrane, Proliferation and 
migration of endothelial cells( Folkman, J et al 149)Capillary tubes are formed that 
anastomose  as  parallel sprouts , loops and new basement membrane are formed 
consequently. 
 
 1. Vasodilation: 
VEGF leads to vascular permeability by stimulating nitric oxide synthase 
(NOS) and increase NO synthesis. Which in turn increase vessel permeability and 
dilation.These changes in the vasculature   increases growth factors sensitivity as 
well as VEGF expression in a positive feedback fashion( Folkman, J et al 149, 
Murohara T et al150)  
 
2.  Basement membrane degradation: 
VEGF increases MMP-1, MMP- 2 and other collagenases by acting directly 
on endothelial cells. The resulting proteolytic enzymes destroys extracellular 
matrix and basement membrane favors endothelial cell migration. 
  
3. Migration of endothelial cells: 
 VEGF leads to chemotaxis of cells and blood vessel dilatation 
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4. Proliferation of endothelial cells: 
VEGF is act as a “mitogen” to endothelial cells selectively.  Nitric oxide 
and cyclic GMP are involved in this signalling (Morbidelli L,et al151)  
Endothelial cell proliferation and its invasion into collagen matrix is aided by 
VEGF ( Goto Fet al 152). “VEGF lengthens the life span of endothelial cells and 
prevents apoptosis. There are some studies showing   temporary anti-apoptotic 
protein expression in human endothelial cells” (Gerber HP et al 153)   
 
5. Wound Healing and VEGF: 
 Granulation tissue formation is vital for normal wound healing and it is 
“the hallmark of an established healing response”. Angiogenesis where new 
vessels are formed depend on. “Inhibition of angiogenesis impairs wound healing” 
(Brem H,et al154) 
 
6. VEGF and Diabetic foot ulcers: 
Though diabetic milieu favors VEGF expression, animal studies with full 
thickness excisional wounds showed early increase in VEGF levels which then 
drop to untraceable levels (Frank S et al 155)  
Diabetic wounds show increased levels of several growth factors like 
VEGF on exposure to PEMF. VEGF promote chemo taxis, angiogenesis, and 
enhance healing. Nitric oxide synthesis is facilitated by PEMF application and it   
mediates VEGF activity and deposition of collagen in diabetic wounds. Also it 
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improves function of endothelial cells, increase tissue oxygenation and nerve 
conduction. PEMF can be used an ideal adjunct therapy for chronic non healing 
diabetic foot ulcers. 
 
Some of clinical application of PEMF:  
A study by Bassett et al156 in Beagle dogs showed enhanced bone repair. 
Wilson & Jagadeesh et al157 in rats with diapulse; 65µsec bursts,80-
600pulses/sec showed  increase of nerve regeneration.  
Bassett et al158 by quasi-rectangular, assymetrical, 300µ pulse width of 75 
Hz 12-16 hrs daily for 3-6 months showed osteogenesis.  
Heckman et al159 ElectroBiology study with quasi-rectangular, assymetrical 
pulses showed 64.4% of healed ununited fractures. 
Binder et al160with 73 + 2 Hz; 2.7 mT (peak) 5-9 hrs daily for  4 weeks 
reduced pain and  improved active range of movements. 
Raji161  in  Rats with diapulse 400 pulses/sec  15 min daily for  3.5 days, 1, 
2, 3, 4, or 8 week accelerated the  rate of recovery of injured nerve, enhanced 
regeneration of damaged nerves  
Sisken et al162 in a rat study showed  sciatic nerve generation. 
[53] 
 
Ieran et al23 showed increase success rate of treating venous skin ulcers; 
reduced recurrence rate  
Stiller et al163 with PELUT,ΔB showed  decreased wound depth and pain 
intensity  
Kaszuba-Zwoińska Jolanta et al164 in human bladder microvascular 
endothelial cell line (HMEVEC-Bd) and MonoMac6 (MM6) cells with 7Hz, 
30mT for three times with 24h intervals  showed decrease of measured cell death 
parameters diminished production of some inflammatory agents.  
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Aim and Objectives 
The aim and objectives of this thesis includes  
Aim: Evaluate of effect of “Pulsed electromagnetic field therapy” in promoting 
healing in chronic non healing diabetic foot ulcers 
Objectives:  
1. To administer Pulsed Electro Magnetic Field therapy to the Diabetic 
Chronic foot ulcer patients  
2. To assess and compare healing parameters after Pulsed Electro Magnetic 
Field therapy  
i. Wound size and dimensions after the treatment 
ii.  Healthy granulation tissue  formation after treatment 
iii. Level of exudation  after  treatment 
iv.  Serum vascular  endothelial growth factor  after the treatment 
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Methods and materials 
This study was conducted during the period of Sep2014- Aug 2015 at the 
Institute of Diabetology and Institute of surgery Rajiv Gandhi Government 
General Hospital Chennai after Institutional Ethics Committee (IEC) clearance is 
obtained from Madras Medical College. 
 Selection of subjects:   
  Thirty patients both men and women in the age group of 40-60 years were 
selected from the department of Diabetology and surgery, Rajiv Gandhi 
Government General Hospital. Diabetic patients, both Type 1 and 2 with foot 
ulcers of Wagner’s grading 1 and 2 of duration  more than 4-6 weeks duration 
participated in the study. Informed consent was obtained from all the patients and 
they were explained about the daily treatment protocol and follow up schedule. 
They were instructed to continue anti diabetic treatment throughout the study 
period.   
Inclusion criteria:   
• Men and women  of Age group 40-60 yrs   
• Diabetic patients  
• Grade1 &2 [Wagner’s]  foot ulcers   
• Duration of foot ulcers more than 4-6 weeks. 
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• Good glycemic control 
• Neuropathic ulcers  
Exclusion criteria  
• Uncontrolled DM 
• Wagner’s grade 3,4,5 ulcers  
• Severely Infected wounds and  Gangrene  
• Neuroischemic ulcers, traumatic ulcers 
• Peripheral vascular disease 
• Coronary artery disease   
• Varicose veins 
• Deep Venous Thrombosis 
• Malignancy  
• Pacemakers  
Study Design: 
Prospective observational Case Control Study 
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Study centre:  
Department of Diabetology & Surgery 
Rajiv Gandhi Government General hospital, Chennai-3 
 
Pulsed magnetic field therapy:  
The equipment consists of a controlled magnetic field system-portable type 
along with its accessories-a signal generator [Make systronics, model 1012, and sr. 
No 4588] and a monitoring meter assembly [oxford 50-0-50mA range]  
 “The coil assemblies, designed and fabricated at Madras Institute of 
Magneto biology are carefully calibrated using high precision magnetometers and 
current measuring devices in the Magnetic Standardization Lab of the institute. 
The high precision measurement involves calibration of the coils for arriving at the 
coil constant expressed in nano- Tesla [nT] per milli –ampere [mA] of current”. 
 The signal generator delivering the current to the coil assembly  is capable 
of operating at 110/120 V, 50Hz at the primary end and at the secondary end  
deliver  currents  [in mA  in the range of 10-100] at desired waveforms  [typically 
sine ,square, and ramp] in varying frequencies  [between 0.1 Hz to 1000Hz at 
voltages between 0.2 to 20 volts] .The meter to measure the current  delivered to 
the coil from the signal generator  is a class 2 type [pre calibrated] milli-ammeter. 
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Pulsed electromagnetic magnetic fields are generated within special 
controlled magnetic field enclosures [coil system] by sending measured amount of 
electric current whose amplitude, frequency and wave form can be controlled 
using signal generators. 
These design guidance equations have been made use of by Fanselau and 
Braunbeck for developing a system of four coils which have the following 
geometry in their mounting. 
The assembly consists of two outer [smaller ] coils of radius  a1 spaced  2d1 
apart and  within these are mounted  two inner [ larger ] coils of radius a2 with 
spacing between them = 2d2, all these bearing specific relation with respect to a1 , 
the coils being of course  coaxial and co-planar  and carrying the same number of 
turns with a single turn of wire in each of these four coil forms all connected in 
“series –aiding “ the system will give a field, 
H= [100X1(number of turns in each coil being=1)   
        0.80852Xa1 (where a1 is expressed in cms)   
for 1millampere of current flowing through them.  
With this assembly, the generated field can be expected to be uniform to as 
good as about 1 part in 5000 or so inside the entire disc shaped volume between 
the two inner [larger] coils of radius, a2.  
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 The four coils form are wound with the two separate  sets of windings : a 
“Steady Field” winding  of 25 turns in each coil and a “pulsation” winding of 6 
turns in each coil , the windings being “series –aiding.” The steady field winding 
gives a coil constant of 40,000nT per ampere of current and the pulsation winding, 
9.6nT per milliamp. 
  The entire coil assembly is mounted on  bearings ,permitting  the  coil  axis 
to swing through 360֯  in the local magnetic meridian .With this system, by  
passing appropriate DC through the steady field winding and with appropriate 
angle of dip  for the coil axis , one can generate inside the coil  assembly, 
magnetic field of any spot on earth [in intensity and direction ]. 
The system  can also  be used for creating  a magnetic vaccum  inside , by 
dipping the axis at the local magnetic inclination  or Dip (+12֯  for Chennai) and 
sending  a current of the right value and direction  to cancel  the local  GMF of 
about 37,000nT. The pulsation winding can be independently energized by a 
function generator to provide a pulsed magnetic field of any desired frequency, 
intensity and waveform inside the enclosure. 
The area /body part to be exposed to the pulsed magnetic fields generated 
inside the coil system is to be placed within the region of most uniform magnetic 
flux density for the prescribed duration of exposure. 
 
  
 
 
 
 
 
                Pic-1 (Portable 
 
 
 
 
 
 
 
PEMF unit with  signal generator
Pic-2(Patient with PEMF Unit) 
) 
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PEMF Safety:  
 The device provides an ultra low intensity (1500nTesla) which is about 
1/40th of normal earth’s magnetic field at extremely low frequencies 
(ranging between 1 to 10 Hz) for therapy.  
 This ensures extreme safety to the patients  
 No radiation is involved 
 It is totally non-invasive 
 Neither medications (internally or externally administered) nor injections 
 No side effects 
Proposed treatment protocol for a duration of 45 min/day for 30 days                                                
• Low current strength  of 30 m A                                        
• Frequency of 10 Hz 
• Wave form of Sine wave  
• Intensity of 1500nT 
• One day break after  every 6 days  
The patients were screened for:  
1. Sensory loss:  
Is accessed by “Modified neuropathy disability score (NDS)”. It is a 
simple, clinical assessment tool which gives quick results. It aims at 
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combination of a number of clinical tests and provides an assessment of the 
neuropathic ulceration risk. Each foot is tested separately and scored 
independently and the results were added together.  
 A score of 10 is said to be maximum which indicates complete loss of sensation   
Score of 6 and more indicate moderate or severe neuropathy   
1.Vibration Perception Threshold 
Tuning fork (128Hz) is applied over  
the apex of the big toe  
Score 0 Score 1 
Normal Abnormal 
 2.Perception of Temperature  
  Beaker of warm or cold water 
applied  over  the dorsum of the foot  
Score 0 Score 1 
Normal Abnormal  
3.Pin prick test  
 Sharp pin applied proximal to the 
big toe nail 
Score 0 Score 1 
Normal Abnormal 
4.Achilles tendon reflex 
 knee hammer tapped on the 
Achilles tendon  
Score 0 Score 1 Score 2 
Present Present with 
reinforcement 
Absent 
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“Biothesiometer or Neurothesiometer: 
This device is simple and hand held that assess vibration perception 
threshold (VPD) semi quantitatively. The patient is comfortably lies in supine 
position and the stylus of the instrument placed on the plantar aspect. Six points 
over plantar surface were checked and the amplitude is increased gradually till the 
patient detect the vibration and the resulting number is called as the VPT. 
VPT more than 15 are regarded as abnormal and higher values of VPT 
“strongly predictive of sensory loss”. 
 
II. Assessment of Biomechanics: 
Presence of Callus graded as Yes   
Absence of Callus graded as No 
 
III. Vascular assessment: 
1. Palpation of posterior tibial artery below and behind the medial malleolus 
bounding pulse  
2. Palpation of dorsalis pedis artery lateral to the extensor hallucis longus 
tendon on the dorsum of foot bounding  
                         
 
 
 
 
 
                                    Pic-3(Biothesiometer) 
 
 
 
 
 
 
 
 
                                     Pic-4 (Assessment of pain) 
  
 
 
 
 
 
Pic-5 (Assessment of vibration sense with128Hz tuning fork) 
 
 
 
 
 
 
 
Pic-6(Ankle jerk) 
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Pulses if present graded as yes, not present as No 
3. Ankle Brachial pressure index: 
A hand held Sphygmomanometer is used 
 ABI measured by dividing the ankle systolic pressure by the brachial systolic 
pressure. 
ABI >0.9 to <1.3 is normal 
 
IV. Ulcer healing parameters:   
1.  Wound Length and Width - longest  and widest aspect of the wound surface 
measured with ruler in cms 
2. Wound Surface area in cm2   or Size  
 
3. Percentage reduction in surface area as calculated as 
 
 Initial surface area – final surface area X100 
 Initial surface area 
4. Depth: Measured by thin sterile metal probe placed perpendicular into the 
lowest section of the wound marked with marker pen read with a ruler in cms 
  
Pic7 (Vascular Assessment) 
 
 
 
 
Pic-8 Butter or tracer paper spread on the wound to measure exudates 
amount  
 
 
 
Pic-9(Ulcer measurement with ruler) 
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5. Tissue type: “This refers to the type of tissue that is present in the wound 
(ulcer) bed and scored as: (4) – Necrotic Tissue (Eschar): black, brown, or tan 
tissue that adheres firmly to the wound bed or ulcer edges and may be either 
firmer or softer than surrounding skin. (3) – Slough: yellow or white tissue that 
adheres to the ulcer bed in strings or thick clumps, or is mucinous.(2) – 
Granulation Tissue: pink or beefy red tissue with a shiny, moist, granular 
appearance.(1) – Epithelial Tissue: New pink or shiny tissue (skin) that grows in 
from the edges or as islands on the ulcer surface.(0) – Closed/Resurfaced: the 
wound is completely covered with epithelium (new skin)”   
                                           Tissue Type Scores 
Tissue Type Score 
Presence of any necrotic tissue   4 
Any amount of slough present 
Absence of necrotic tissue 
3 
 Clean wound 
 Granulation tissue present  
2 
Wound  is superficial 
Re-epithelializing  tissue 
1 
Wound  closed 0 
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6. Level of exudation is calculated by placing a butter (or) tracer paper spread on 
to the wound area and amount of soaking is seen and scored as  
                                            Exudation Scores 
None 0 
Light 1 
Moderate 2 
Heavy 3 
 
Grading of tissue type and exudates amount is followed from  
Pressure Ulcers: Scale for Healing (PUSH)  
V. Probe to bone test: Done with a sterile metallic probe to rule out 
osteomyelitis. 
VI. Serum VEGF levels assessed before and after PEMF therapy  
Blood samples are collected, serum separated by centrifuging and stored at desired 
temperature.  
Assessment of serum VEGF: 
 VEGF ELISA (Enzyme-Linked Immunosorbent Assay) kit was used to 
assess serum VEGF levels. This procedure is an in vitro enzyme –linked 
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immunosorbent assay and it measures humanVEGF levels in the serum 
quantitatively.  
 
Principle:  
This assay is based on the principle of using an antibody that is specific for 
human VEGF which is coated on a 96-well Elisa plate.  The standards and 
samples were pipetted into the wells and if VEGF is present in the sample it will 
get bound to the wells by the immobilized antibody. The wells were washed and 
then added with biotinylated anti-human VEGF antibody.  
 Unbound biotinylated antibody also washed then HRP-conjugated 
streptavidin was pipetted into to the wells. The wells were again washed, a TMB 
substrate solution then added to the wells. There will be development of a colour 
in proportion to the amount of bound. Then stop solution is added which changes 
blue colour  to yellow, and the intensity of the colour developed  is measured at a 
wave length of  450 nm. 
 
 II. The reagents provided with Kit 
1. “VEGF-A Microplate (Item A): 96 wells (12 strips x 8 wells) coated with anti-
Human VEGF-A. 
2. Wash Buffer Concentrate (20X) (Item B): 25 ml of 20X concentrated solution. 
3. Standard Protein (Item C): 2 vials of Human VEGF-A. 1 vial is enough to run 
each standard in duplicate. 
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4. Detection Antibody VEGF-A (Item F): 2 vials of biotinylated anti-Human 
VEGFA (each vial is enough to assay half microplate). 
5. HRP-Streptavidin Concentrate (Item G): 200 μl 300X concentrated 
HRPconjugated streptavidin. 
6. TMB One-Step Substrate Reagent (Item H): 12 ml of 3,3,5,5' 
tetramethylbenzidine (TMB) in buffer solution. 
7. Stop Solution (Item I): 8 ml of 0.2 M sulfuric acid. 
8. Assay Diluent A (Item D): 30 ml of diluent buffer, 0.09% sodium azide as 
preservative. 
9. Assay Diluent B (Item E): 15 ml of 5X concentrated buffer”. 
 
The Materials required are: 
1.  A microplate reader which is capable of measuring the absorbance at a 
wavelength of 450 nm. 
2. Precision pipettes that deliver two microlitre  to one millilitre volumes. 
3.  1-25 ml adjustable pipettes for preparation of the reagent 
4. Graduated cylinders. 100 ml and 1 litre 
5. Absorbent paper.  
6. Distilled water or deionized water 
7. Computer and software for ELISA data analysis or Log-log graph paper 
8.  Test tubes for preparing sample or standard dilutions  
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Assay procedure: 
1. Reagents, samples and standards were  prepared as instructed. 
2.  100 μl of standard or sample are added to each to well then incubated for 
21/2 hour at room temperature or at 4֯ C for overnight 
2.100 μl of prepared biotin antibody is added to each well then incubated for 
1hour at the room temperature. 
3.100 μl of prepared Streptavidin solution added and incubate for 45 minutes 
at the room temperature. 
4.100 μl of TMB One -Step Substrate Reagent is added to each well and 
incubated for 30 minutes at the room temperature. 
5. 50μl of Stop Solution is added to each well then read immediately at the 
wavelength of 450 nm 
 
Results Calculations: 
The mean absorbance is calculated for each set of samples duplicate 
standards and controls. The average zero standard optical density is subtracted.  
The standard curve then plotted on a log -log graph paper or using Sigma plot 
software. Standard concentrations were drawn on the x-axis and absorbances were 
drawn on the y-axis.. All the results were calculated and mean and standard 
deviation was estimated.  
  
 
 
 
 
 
 
 
Pic-10 (VEGF KIT AND ELISA READER) 
 
 
 
 
 
  
Pic-11(Ulcer Before and after treatment) 
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The minimum detectable dose of Human VEGF-A was determined to 
be 10pg/ml                                              
 
Statistical Analysis: 
The data collected were subjected to Statistical analysis using the software 
SPSS version 21. All the results are calculated and mean and standard deviation is 
estimated. Paired t’ test was carried out to compare the means of variables 
between pre treatment and post treatment 
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RESULTS 
Table I 
Demographic data and base line data  (n)=30 
 Mean Age (years)  55.1±5.01 
Age range (years) 43-60 
Number of men 23 
Number of women 7 
Mean duration of Diabetes(yrs) 7.8±1.47  
Mean ulcer duration(months) 4.9±1.2 
 FBS 118.2±7.31 
PPBS 147.7±13.9 
Systolic  BP 128.3±9.499 
Diastolic  BP 84.867 ±4.8904 
 
With Callus foot 6 
Wagner’s classification Grade 1 Grade 2 
16 14 
Ulcer location Plantar 14 
Heel 11 
Toes 2 
Leg 3 
  
 The patients demographic data given in the table 1 shows that the 
study group included thirty patients (M: F, 23:7) with mean age of 55.06±5.01 yrs. 
The mean duration of Diabetes is 7.8 ±1.47 yrs and the mean duration of ulcer is 
4.9±1.2 months. 
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 Sixteen were grouped under Wagner’s 1 and fourteen are grouped 
under Wagner’2 grading. Among them fourteen had plantar ulcers, eleven had 
heel ulcers, two had toes ulcers and three had leg ulcers showing the more 
prevalence of plantar ulcers in this study group. Six patients had callus foot. 
 None of the patients were not complain of adverse effects and their 
compliance was good throughout course of the treatment.  
 The patients showed overall 66% ±15% reduction in the wound 
surface area. Less than 50 % reduction is reported in 2 of the patients. About 50-
59% reduction is noted in 6 patients, 11 patients showed 60-69% reduction, 7 
patients showed 70-79% reduction, 2 patients more than 90% reduction and 2 
patients showed 80-89% reduction in the wound area. 
 None reported any worsening of the symptoms. 
 
TABLE-2 
Comparison  of healing Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
LENGTH 
pre 30 2.5 1.2 
0.0004** 
post 30 1.5 0.8 
** P – Value < 0.000 Very Highly Significant 
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The wound length shows very high statistically significant reduction at the 
end of the therapy from the base line value (** P – Value < 0.000) 
TABLE-3 
Comparison  of healing Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
WIDTH 
pre 30 1.47 .60 
0.0001** 
post 30 .8 .40 
** P – Value < 0.0001 Very Highly Significant 
The wound width shows very high statistically significant reduction at the 
end of the therapy from the base line value (** P – Value < 0.0001) 
TABLE-4 
Comparison  of healing Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
SURFACE 
AREA 
pre 30 4.2 2.8 
0.0001** 
post 30 1.54 1.0 
** P – Value < 0.0001 Very Highly Significant 
The wound surface area shows very high statistically significant reduction 
at the end of the therapy from the base line value (** P – Value < 0.0001) 
 
Graph.1. Comparison of means of ulcer length before and after PEMF   
 
 
 
 
Graph.2. Comparison of means of ulcer width before and after PEMF   
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                                                TABLE-5 
                            Comparison  of healing Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
DEPTH 
pre 30 0.66 .19 
0.0001** 
post 30 0.33 .2 
** P – Value < 0.0001 Very Highly Significant 
The wound depth shows very high statistically significant reduction at the 
end of the therapy from the base line value (** P – Value < 0.0001). 
 
                                                TABLE-6 
                            Comparison  of healing Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
TISSUE 
TYPE 
pre 30 3 0 
0.0001** 
post 30 1.76 0.61 
** P – Value < 0.0001 Very Highly Significant 
There is very high statistically significant change in the tissue type at the 
end of the therapy from the base line value (** P – Value < 0.0001) 
 
 
Graph.3. Comparison of means of ulcer surface area before and after PEMF 
 
 
 
 
Graph.4. Comparison of means of ulcer depth before and after PEMF   
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TABLE-7 
Comparison  of healing Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
EXUDATE 
AMOUNT 
pre 30 1.4 0.48 
0.0001** 
post 30 0.16 0.37 
** P – Value < 0.001 Very Highly Significant 
There is very high statistically significant decrease in exudation at the end 
of therapy from the base line (** P – Value < 0.0001) 
TABLE-8 
Comparison  of serum VEGF ƥg/ml levels  Before and after  treatment 
VARIABLE Group N Mean SD P-VALUE 
VEGF 
pre 30 33 12.4 
0.0001** 
post 30 639.1 238 
** P – Value < 0.0001 Very Highly Significant 
There is very high statistically significant increase in serum VEGF levels at 
the end of therapy from baseline (** P – Value < 0.0001) 
 
 
 
 Graph.5. Comparison of means of ulcer tissue type before and after PEMF 
 
                      
 
                     
Graph.6. Comparison of means of ulcer exudate before and after PEMF 
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TABLE-9 
Comparison of NDS Before and  after treatment  
VARIABLE Group N Mean SD P-VALUE 
NDS 
pre 30 7.3 0.915 
0.0001** 
post 30 2.2 0.664 
** P – Value < 0.0001 Very Highly Significant 
There is very high statistically significant reduction in NDS values at the 
end of therapy from baseline (** P – Value < 0.0001) 
TABLE-10 
Comparison of Biothesiometer  Before and  after treatment  
VARIABLE Group N Mean SD 
P-
VALUE 
BIOTHESIOMETER 
pre 30 25 3.1 
0.0001** 
post 30 12.16 2.53 
** P – Value < 0.0001 Very Highly Significant 
There is very high statistically significant reduction in Biothesiometer 
values at the end of therapy from baseline (** P – Value < 0.0001) 
 
 
Graph.7. Comparison of means of ulcer VEGF levels before and after PEMF 
 
 
 
 
 Graph.8. Comparison of means of ulcer NDS before and after PEMF                                                      
 
                                                    
 Graph.9. Comparison of means of vibration perception threshold before and 
after PEMF 
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DISCUSSION 
This study was conducted to evaluate the effect of Pulsed Electromagnetic 
Field Therapy in chronic non healing diabetic foot ulcers.  
 
Healing was assessed by  
 Reduction in wound size and dimensions      
 Formation of healthy  Granulation tissue 
 Reduction in level of exudation 
 Increase in serum VEGF levels 
Though debridement and off loading are the conventional methods to treat 
chronic diabetic foot ulcers their efficacy remains uncertain. This raised the need 
for intervention with PEMF.  
 
Reduction in wound size and Dimensions:  
Treatment with low frequency low intensity Pulsed Electro Magnetic Fields for 
45 minutes/day for 30 days showed significant reduction in wound length, width, 
surface area which is consistent with the study by stiller et al163.  
Kenkre JE et al165 conducted a randomized trial of case control study in 
primary care venous leg ulcers. Exposure to electromagnetic fields for 30 days has 
resulted in reduction in mean ulcer area and some ulcers completely healed. 
A study by Ieran et42 al pulsed electromagnetic field therapy for a duration of   
90 days reported significant healing in venous ulcers.    
[77] 
 
Formation of healthy granulation tissue: 
There was a change in tissue type from slough to granulation tissue in almost 
all the patients showing improvement in healing which is consistent with the study 
by stiller et al163.  
 Ian M Rawe et al166 observed a steady decrease in wound size as well as 
decrease in visible peri wound edema.  
In both the studies of Stiller et al163 and Ian M Rawe et al166 all the patients 
were well tolerated therapy without any adverse effects.  
 This study showed that PEMF therapy is safe and effective in healing chronic 
diabetic foot ulcers.  
Canaday and Lee et al167 have proved that PEMF accelerated wound healing in 
chronic ulcers. 
PEMF therapy increase cellular metabolism and hence increase mitosis of 
various cells such as fibroblasts and endothelial cells by applying certain 
frequencies and intensity. This could be the reason for the improved healing of 
soft tissue in this study (Brette wade et al168) 
There are many in vitro studies showing diverse cellular responses to PEMF 
which are relevant to wound healing.  
Fibroblasts and epithelial cell culture, on exposure to electric fields migrated 
perpendicular to the applied field. This could be the reason for healing in this 
study which involves the migration of fibroblasts and epithelial cells to the wound 
site. 
[78] 
 
For normal immune system an acute inflammation is necessary.  But chronic 
inflammation seen in diabetes can be detrimental. PEMF able to treat this 
condition as a non-invasive, low-cost, easy-to-use complement or alternative to 
currently prescribed treatments (Christina L. Ross et al 169) 
 
Improvement in Sensation: 
  A significant reduction in Neuropathy Disability Score and Vibration 
Perception Threshold observed is consistent with the study by Wintrobe et al170 
and E.Bosi et al171. 
In a study by Wintrobe et al170 with  pulsed electromagnetic field therapy  there 
was a reduction in diabetic neuropathic pain and stimulated neuronal repair, fourty 
five  percent reduction in DPN symptoms and twenty-nine percent of   them had 
increase in distal leg ENFD (epidermal nerve fiber density) in PEMF group while 
nil results in  sham group. 
E. Bosi et al171 showed a significant reduction in day time and night –time 
VAS pain score, improved   perception of vibration sense and nerve conduction in 
motor neurons.  
The improvement in sensory perception as evidenced by reduction in NDS 
scores and Vibration Perception Threshold could be due to release of vaso active 
factors. These resulted in an increase endo-neural blood flow.  
 
 
[79] 
 
Vascular endothelial Growth Factor: 
Usually diabetes is associated with a decrease in growth factors, especially 
VEGF levels (Veves A et al172). 
This study showed a elevation in serum VEGF levels which is consistent with 
an animal study by Meade et al showing the effect of Pulsed Electro Magnetic 
Field (PEMF) upon fracture healing in diabetic rats. The rats were treated with 
PEMF had significant elevated levels of   PDGF, IGF-1 and VEGF levels in the 
fracture callus which showed the importance of growth factors in early healing.  
Angiogenic growth factors in bone marrow are up-regulated by Pulsed Electro 
Magnetic Fields stimulation by  in an animal study showed no observed difference 
in the levels of VEGF with PEMF treated mice but PEMF led to an increase in 
FGF-2 and Ang-2 but decreased VEGF in mice femoral medulla. 
In vivo study by OrenM.et al, matrigel plug assay exposed to electromagnetic 
fields showed in growth of vessels after 2weeks of exposure to PEMF. 
Low dose pulsed magnetic fields to human umbilical vein endothelial cells   
has resulted in endothelial cell   proliferation and endothelial tubule formation.  
The ability of PEMF to increase cellular proliferation was unique to 
endothelial cells. This suggests that endothelial cells are a primary target of PEMF 
stimulation, releasing protein in a paracrine fashion to induce changes in 
neighboring cells of different lineages and up-regulating angiogenesis. This could 
be the reason for elevation of VEGF in this study. 
[80] 
 
In an another study by  Chang-Ning Hao et al168 found that induced 
myocardial infarction on exposure  PEMF  increased density of the capillaries, 
elevated  vascular endothelial growth factor. 
 In vitro studies with umbilical vein endothelial cells showed that PEMF 
lead to tubulization and increased Nitric oxide and VEGF secretion and also 
increased endothelial precursor cells. 
Smith et al used a PEMF with positive and negative 18.8 T/s and examined 
acute changes in arteriole diameter for 2 minutes exposure which showed nine 
percent increase in the diameter which is increased further on continuation for 
another 60 minutes. 
In a study by Cecilia Y Webb et al169 showed that treatment with magnetic 
fields of low intensity and low frequency resulted in significant increase in blood 
flow and oxygen tension.  
  
 
 
 
 
 
 
 
 

[81] 
 
CONCLUSION 
This study concluded that PEMF used effectively as a safe adjunct 
treatment modality in chronic diabetic foot ulcers. 
 From various cellular, animal experiments and from human studies it is 
evident that PEMF therapy linked positively with wound healing processes and 
outcomes. It is also suggested that its use has relieved wound pain and improved 
neuropathy in diabetic patients. 
Further studies showed elevation in growth factors such as VEGF. 
None of the cases reported with any adverse effects.  
Easy application, lack of adverse effects, proven clinical and case studies 
suggest this intervention used as an adjunct therapy for treating diabetic wound 
foot ulcers. 
            Further studies with randomized control trials are needed to evaluate 
PEMF therapy for diabetic foot ulcers.  
 
 
 
 
 
 
 
 

[82] 
 
SUMMARY 
        To summarize, diabetes is a common metabolic endocrine disorder emerging 
as an epidemic throughout the world and is characterized by various dreadful 
complications. 
         One such dreaded complication diabetic poly neuropathy leads to foot 
changes, sensory deficit and micro vascular changes resulting in diabetic foot 
ulcer. 
         Once developed it is very difficult to treat them due to repeated trauma, 
infection and ischemia. The deformities that develop in the foot interfere with 
normal gait, loss of soft tissue support in plantar aspect leads to pressure points. 
All these changes finally result in chronic ulcer that fails to heal.  
          The chronic nature of diabetic foot ulcer is due to arrest of inflammation, 
loss of balance between extracellular matrix degradation and deposition, defective 
angiogenesis and failure of growth factors synthesis and their function. 
         These patients are more prone to develop infections and gangrene that 
ultimately ends in amputation of the affected limb. 
         Conventional therapies fail to treat these ulcers. 
         These aspects lead to the development of eletrophysical modalities like 
pulsed electromagnetic fields to treat diabetic ulcers. 
        It is suggested that PEMF acts at cellular level, induce electrical currents in 
the melieu of wound fluid and influence various steps in the healing and hasten it. 
[83] 
 
                    It targets at various growth factors such as vascular endothelial 
growth factor which play a role in the new blood vessel formation that play an   
essential role in wound healing. 
                    Thus pulsed electromagnetic field therapy is a non invasive, safe and 
effective method of adjunct treatment for diabetic foot ulcers. 
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INFORMED CONSENT FORM 
 
Title of the study“Evaluation of the effect of Pulsed Electro Magnetic Field 
Therapy in Chronic non healing Diabetic foot ulcers”  
Name of the Participant:  
Name of the Principal Investigator: Dr. AMARESWARI V.H. 
Name of the Institution:  
          Institute of Physiology and Experimental Medicine, 
          Madras Medical College and Govt. General Hospital, 
          Chennai - 3 
 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been 
answered. I am over 18 years of age and, exercising my free power of choice, 
hereby give my consent to be included as a participant in 
 
“Evaluation of the effect of Pulsed Electro Magnetic Field Therapy in chronic 
non healing diabetic foot ulcers” 
 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms.  
8. I have not participated in any research study within the 
past________month(s).  
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital.  
10. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent.  
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
13. I have understood that my identity will be kept confidential if my data are 
publicly presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in 
this document has been clearly explained to mean and understood by me, I will 
be given a copy of this consent document. 
 
For adult participants: 
 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                PROFORMA 
1. Name: 
2. Age: 
3. Sex: 
4. Address                        
5. H/o Smoking/Alcohol/DM/HT 
6. H/o Heart disease/Pace maker /PVD/Venous ulcers 
7. Duration of diabetes: 
8. Treatment for diabetes: On hypoglycemic drugs Yes/No 
9. FBS: 
10. PPBS: 
11. Urea: 
12. Creatinine: 
13. BP: 
14. Duration of ulcer: 
15. Callus: Present (or) Absent 
16. Sensory Loss (NDS) score: 
17. Biothesiometer 
18. Bounding Peripheral Pulses:  
19. Ankle brachial index:  
20. Bone to probe test: 
21. Wagner’s Grade: 1or 2 
22. Ulcer site: (Right or Left), (Plantar or Heel or Toes or Leg) 
23. Ulcer length in cm: 
24. Ulcer width in cm: 
25. Ulcer surface area in cm2: 
26. Tissue type: Necrotic tissue or Slough or Granulation tissue or Epithelial tissue 
or closed 
27. Exudate amount: None or light or Moderate or Heavy 
28. Serum VEGF levels: 
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20 55 male 5 6 110 130 130 80 N N 8 1 25 15 Y 1 N 1   1 0.5 0.4 0.5 0.3 0.25 0.12 52% 0.4 0.2 3 2 1 1 20 100 
21 60 female 8 4 120 160 140 90 N N 7 3 25 10 Y 0.9 N   2 2 2.5 2 1.7 1 4.25 2 53% 0.8 0.4 3 1 2 0 30 575 
22 55 male 8 6 110 148 130 80 Y N 9 3 30 15 Y 1 N 2   2 4 3.5 1 0.8 4 2.8 28% 0.8 0.6 3 3 2 1 20 80 
23 60 female 7 6 110 138 130 80 N N 9 4 30 10 Y 0.9 N   1 1 1 0.5 1 0.5 1 0.25 75% 0.6 0.3 3 1 2 0 10 600 
24 48 male 7 5 120 150 120 90 N N 7 2 25 15 Y 0.9 N 1   1 4 2.5 2.5 1.5 10 3.75 63% 0.6 0.3 3 2 1 0 30 575 
25 58 male 6 4 110 130 130 90 N N 8 2 25 10 Y 0.9 N   1 2 2.5 1.5 1.5 0.9 3.75 3.75 64% 1 0.4 3 2 1 0 20 700 
26 52 male 7 4 110 140 140 80 N N 8 2 25 15 Y 1 N 2   2 2.5 1.2 1.5 1 3.75 1.2 62% 0.8 0.3 3 1 1 0 50 625 
27 58 male 6 4 106 150 120 90 N N 8 2 25 10 Y 0.9 N   2 1 1 0.5 1 0.5 1 0.25 75% 0.8 0.5 3 2 1 0 50 900 
28 56 female 7 4 110 140 130 80 N N 8 2 25 10 Y 1 N 2   1 1 0.8 1 0.5 1 1 60% 0.5 0.2 3 1 1 0 40 625 
29 60 female 8 5 120 150 130 80 N N 8 2 25 15 Y 1 N   1 1 1.5 0.8 1 0.6 1.5 0.48 68% 0.6 0.2 3 2 1 0 30 750 
30 60 male 8 6 110 138 120 80 N N 8 4 25 10 Y 1 N 2   2 3.5 2.5 1.2 0.8 4.2 2 52% 0.8 0.4 3 2 2 0 30 450 
 
